Airway Therapeutics

Airway Therapeutics, Inc. is a biopharmaceutical company focused on developing protein therapeutics for lung and pediatric applications. Based in Cincinnati, Ohio, with additional offices in Marietta, Georgia, the company specializes in products like recombinant human surfactant protein-D, aimed at preventing bronchopulmonary dysplasia in premature infants, and AT100, a protein replacement therapy for the same condition. The company licenses technology from the pulmonary research program of Cincinnati Children's Hospital Medical Center, which supports the development of multiple products targeting various lung disorders. Airway Therapeutics aims to address the cycle of injury and inflammation in patients with respiratory and inflammatory diseases through advanced biologics that reduce inflammation, infection, and modulate immune responses, ultimately improving treatment outcomes.